EYPT250117C10000
- 0.10
- -0.08-44.44%
EyePoint Pharmaceuticals Newsroom
Optimistic Buy Rating for EyePoint Pharmaceuticals: Potential of Duravyu in Diabetic Macular Edema
EyePoint Pharmaceuticals Strengthens Board With New Appointment
Express News | EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.d., Fasrs to Board of Directors
EyePoint Appoints Reginald Sanders to Board of Directors
EyePoint Initiated at Buy by Citi on WAMD Drug Potential
Citi Initiates EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $33
EyePoint Pharmaceuticals: Positioned for Growth With DURAVYU in the WAMD Market
Investors in EyePoint Pharmaceuticals (NASDAQ:EYPT) From a Year Ago Are Still Down 60%, Even After 15% Gain This Past Week
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $22
EyePoint Pharmaceuticals Price Target Maintained With a $22.00/Share by HC Wainwright & Co.
EyePoint Pharmaceuticals Analyst Ratings
Express News | EyePoint Pharmaceuticals Inc - Topline Data for Phase 3 Pivotal Program Expected in 2026
Express News | EyePoint Announces First Patient Dosed in Second Global Phase 3 Lucia Clinical Trial of Duravyu™ for the Treatment of Wet Age-Related Macular Degeneration
EyePoint Pharmaceuticals Poised for Growth With Promising DME Treatment Duravyu
Some EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shareholders Look For Exit As Shares Take 27% Pounding
Selling EyePoint Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Express News | EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?
Baird Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $33